Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

7 are currently without
evidence of disease.

No non-hematologic Grade 4 adverse events were reported. Grade 4 lymphopenia, neutropenia
and thrombocytopenia were observed in 1, 2 and 2 patients, respectively. Grade 1-3 anemia,
nausea/vomiting and hypocalcemia were observed in 18, 1, and 3 patients, respectively.
“Myelosuppression, particularly neutropenia, is a substantial clinical problem in patients with
relapsed NHL,” said Dr. Scott E. Smith, MD, PhD, Assistant Professor of Medicine at Loyola,
who was the principal investigator of this trial. “Based on these favorable results, we have
organized a followup trial of GaRD used in combination with another standard regimen that we
expect to initiate in a Chicago-based clinical collaboration.”

About Ganite
Ganite was originally developed by the U.S. National Cancer Institute as a cancer chemotherapy
drug. A separate series of studies showed that the drug markedly reduced the loss of calcium
from bone - an observation that suggested the drug may be useful in hypercalcemia, as well as
other conditions associated with loss of bone mass. Ganite is approved in the U.S. for treatment
of symptomatic patients with cancer related hypercalcemia that is resistant to hydration.

Important Safety Information about Ganite® (gallium nitrate injection)
Ganite is contraindicated in patients with severe renal impairment (serum creatinine > 2.5
mg/dL). While Ganite was generally well tolerated by patients who received the drug in clinical
trials, concurrent use of Ganite with other potentially nephrotoxic drugs like aminoglycosides
and amphotericin B may increase the risk for developing severe renal insufficiency in patients
with cancer-relapsed hypercalcemia. If use of a potentially nephrotoxic drug is indicated during
Ganite therapy, Ganite should be disconti
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/16/2014)... 2014 A study led by St. ... chemotherapy dose threshold below which male childhood cancer survivors ... appears in September 17 edition of the journal ... are at highest risk for reduced sperm production as ... of pre-treatment fertility preservation methods such as sperm banking. ...
(Date:9/16/2014)... Ill. , Sept. 16, 2014 ... new director of Business Communications & Advocacy, Urology ... President, Business Communications & Advocacy Margaret Long. In this ... commitment to urology to patient and advocacy organizations, ... teams on key strategic initiatives. Noland,s appointment is ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Dan ... GWM Products, LLC, manufacturer of the RTD ® ... plan to expand its sales presence in the U.S. ... hiring and training direct field sales representatives in new ... The company plans to add up to 20 sales ...
Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... Va., Oct. 30 CEL-SCI Corporation,(Amex: CVM ) ... at the Rodman & Renshaw 9th Annual Healthcare Conference ... 5-7, 2007. The presentation,will be focused on its Phase ... product seeking to become a new first line standard ...
... the Potential ... INDIANAPOLIS and MUMBAI, India, Oct. 30 Eli,Lilly and Company ... into an,agreement with Glenmark Pharmaceuticals S.A. (GPSA) a wholly owned,subsidiary ... agreement, Lilly will acquire the rights to a portfolio of ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 3Lilly and Glenmark Pharmaceuticals Announce License Agreement 4Lilly and Glenmark Pharmaceuticals Announce License Agreement 5
(Date:9/16/2014)... Dog Food Secrets , a guide compiled ... ingredients in most commercial dog food but presents a better ... of Shane Michaels, prompting an investigative review. , “For ... family member as any other human is, which is why ... should due to poor diet” reports Michaels. “Most dog owners ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 Operation Smile was ... die because of a facial deformity.” To spread their message ... September 19, 2014, at the Beverly Wilshire Hotel in Beverly ... young people worldwide whose lives have been forever transformed by ... to be involved with Operation Smile,” said Lynda Erkiletian, Executive ...
(Date:9/16/2014)... In a healthcare climate where the costs ... a Yale study has found that radiation oncologists ... elderly women with early-stage breast cancer. The findings ... annual conference of the American Society for Radiation ... Practice in Radiotherapy for Elderly Women: Response to ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... Not all recovery plans are alike, and ... sure all their patients are receiving the treatment that ... the newly-introduced online therapy. Millennium Treatment Group recently launched ... opportunity to seek treatment from home. , With online ... care at a distance. They provide patients with all ...
Breaking Medicine News(10 mins):Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:James & Paula Coburn Foundation to Host the 2014 Smile Gala, Presented by Operation Smile 2Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Now Offers Online Therapy 2
... Walk on the Capitol,is proud to announce Caitlin Van ... guest speaker for our National obesity awareness event,in Washington, ... Capitol is a,history-making awareness event that will gather thousands ... the obesity epidemic and,the need for expanded efforts in ...
... 2 ,Dawning Technologies, Inc. (Dawning) and Medical Automation ... joint project to leverage their,product synergies and create ... project will focus on the seamless integration of ... RALS(R)-,Plus POC Data Management solutions. RALS-Plus is a ...
... Merger, CHICAGO, June 2 Allscripts, the ... that,physicians use to improve healthcare, announced today that ... Act of,1976, with respect to the merger agreement ... Healthcare to form Allscripts-Misys Healthcare,Solutions, Inc., has expired., ...
... MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure ... company developing,high-value human plasma-derived protein products for ... quarter results., Financing, As a ... to-date from key,shareholders to exercise their Series ...
... care deserves more funding for estimated 2.5 million displaced ... removed from their homes due to mistreatment have fewer ... kinship care -- than if they,re placed in foster ... by researchers at Children,s Hospital of Philadelphia, looked at ...
... are similar to the type diagnosed in Sen. Edward ... experimental cancer vaccine is showing promise against the same ... Kennedy, researchers are reporting. , The vaccine, when given ... with glioblastoma multiforme tumors. Kennedy was diagnosed last month ...
Cached Medicine News:Health News:Television Star Caitlin Van Zandt Signs-on as Special Guest Speaker for National Obesity Awareness Event in Washington, DC, on June 17 2Health News:Dawning Technologies, Inc. and Medical Automation Systems, Inc. to Develop a Business Partnership 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 3Health News:Kids Living With Relatives Have Fewer Problems Than Those in Foster Homes 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... White solid. Highly purified non-ionic fraction of ... at very low concentrations. Can be mounted ... dried, films are elastic and durable and ... with either protein or lipoprotein dyes. ...
Medicine Products: